Michael Harty (Clare, Independent) | Oireachtas source

There were some questions that we might just park for the moment because the Deputies who asked them have left relating to FDA and marketing policy in the US, different standards of assessment for orphan drugs, drug pricing negotiations which I think Professor Barry referred to and duplication of evaluations. We will leave those and bring in other members who have not had an opportunity to speak yet.